合成明膠包覆中孔洞氧化矽奈⽶粒子應⽤於酵素響應藥物控制釋放系統:探討載體對人類口腔鱗狀上皮細胞癌之細胞毒殺及活體動物試驗

Synthesis of Gelatin-Capped Mesoporous Silica Nanoparticles for Enzyme-Responsive Drug Delivery System: In vitro and In vivo Study of Human Oral Squamous Cell Carcinoma

10.6342/NTU.2015.02900

許雲東

中孔洞氧化矽奈⽶顆粒 ； 藥物運送 ； 明膠包覆 ； 控制釋放 ； Mesoporous silica nanoparticle ； drug delivery ； gelatin coating ； stimuli-responsive controlled-release

國立臺灣大學口腔生物科學研究所學位論文

2015年

碩士

張正琪

英文

本研究利用明膠附著在中孔洞氧化矽奈米顆粒的表面(MSN@Gel)，透過基質金屬蛋白脢2 (MMP2) 可以將明膠分解的特性讓此系統可應用在口腔癌的治療中，在內生性腫瘤微環境的刺激下做藥物的控制釋放。明膠在此藥物釋放系統中扮演著一層保護膜避免藥物提早釋放且腫瘤微環境中有大量表現MMP2能將MSN表層的明膠慢慢降解而達到控制性的藥物釋放。順鉑(Cisplatin)是本實驗的抗癌藥物，MSN搭載cisplatin包覆明膠(Cis/MSN@Gel)應用在MMP的催化下做控制性藥物釋放。因為細胞的內吞作用而使搭載在載體內的cisplatin能夠更輕易的被細胞攝入，載體特性可以增加細胞攝入抗癌藥物的量，來達到降低藥物在體內的用量。在口腔鱗狀上皮癌（SAS cells）細胞實驗中，相較於cisplatin，實驗結果也顯示出細胞攝入cisplatin的量在搭配載體後高出1.55倍。在細胞活性測驗中，相較於cisplatin，Cis/MSN@Gel在較低的濃度中即可表現出細胞毒性。此外，透過活體動物實驗分析Cis/MSN@Gel對腫瘤生長的影響，結果顯示相較cisplatin，Cis/MSN@Gel更能在SAS皮下異種移植之腫瘤小鼠模式中抑制腫瘤生長。本研究展現Cis/MSN@Gel具有抑制癌細胞腫瘤生長和小鼠體重驟降的潛力。因此，Cis/MSN@Gel具有潛力成為開發癌症用藥、治療癌症的新材料。

In this study, the system of gelatin-coated mesoporous silica nanoparticles (MSN@Gel) was degraded by matrix metalloproteinase 2 (MMP2) to be designed for the endogenous tumor microenvironment-triggered release systems of oral cancer treatment. The gelatin coating on MSN causes the MMP2-digested substrates to respond to the solid tumor microenvironment and acts as a protective layer to prevent the leakage of drugs. As an antitumor drug, the encapsulated cisplatin in the Cis/MSNs@Gel was greatly delivered into the cancerous cells due to the endocytosis activity of delivery system, which could increase the amount of cellular uptake and alleviate systemic toxicity during the therapeutic treatments. In vitro studies show that the intracellular drug delivery efficiency was greatly enhanced (i.e. 1.55 folds) for the Cis/MSN@Gel drug delivery system compared to free cisplatin in the squamous cell carcinoma (SAS cells). Moreover, Cis/MSN@Gel displays toxicity in lower concentration compared to free cisplatin in SAS cells. Furthermore, in vivo studies reveal that the tumor growth of subcutaneous SAS xenogeneic tumor mice (SCID) treated with Cis/MSN@Gel is significantly delayed without any distinct body weight loss, which show the lower systemic toxicity of Cis/MSN@Gel compared to that of free cisplatin. Thus, this drug delivery system will provide a great potential for developing delivery of oral cancer therapeutic agents.

1. 1. Calixto G, Bernegossi J, Fonseca-Santos B, Chorilli M (2014) Nanotechnology-based drug delivery systems for treatment of oral cancer: a review. Int J Nanomedicine 9: 3719-3735.
   連結：
2. 2. Terry A. Day M, FACS et al., (2003) Oral caner treatment.
   連結：
3. 3. Zakrzewka JM (1999) Oral cancer. BMJ 318.
   連結：
4. 4. Siegel R, Naishadham D, Jemal A (2012) Cancer statistics, 2012. CA Cancer J Clin 62: 10-29.
   連結：
5. 5. Adelstein DJ (2003) An Intergroup Phase III Comparison of Standard Radiation Therapy and Two Schedules of Concurrent Chemoradiotherapy in Patients With Unresectable Squamous Cell Head and Neck Cancer. Journal of Clinical Oncology 21: 92-98.
   連結：
6. 6. Bagri PK, Kapoor A, Kalwar A, Singhal MK, Singh D, et al. (2014) Comparative analysis of cisplatin-induced nephrotoxicity in head and neck cancer and carcinoma cervix during concurrent chemoradiotherapy. South Asian J Cancer 3: 217-220.
   連結：
7. 7. Vermorken JB, Trigo J, Hitt R, Koralewski P, Diaz-Rubio E, et al. (2007) Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol 25: 2171-2177.
   連結：
8. 8. Agueros M, Ruiz-Gaton L, Vauthier C, Bouchemal K, Espuelas S, et al. (2009) Combined hydroxypropyl-beta-cyclodextrin and poly(anhydride) nanoparticles improve the oral permeability of paclitaxel. Eur J Pharm Sci 38: 405-413.
   連結：
9. 9. C.M.F. KRUIJTZER, J.H. BEIJNEN, SCHELLENS JHM (2002) Improvement of Oral Drug Treatment by Temporary Inhibition of Drug Transporters and/or Cytochrome P450 in the Gastrointestinal Tract and Liver: An Overview. The Oncologist.
   連結：
10. 10. Kelland L (2007) The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer 7: 573-584.
    連結：
11. 11. He H, Xiao H, Kuang H, Xie Z, Chen X, et al. (2014) Synthesis of mesoporous silica nanoparticle-oxaliplatin conjugates for improved anticancer drug delivery. Colloids Surf B Biointerfaces 117: 75-81.
    連結：
12. 12. Kou L, Sun J, Zhai Y, He Z (2013) The endocytosis and intracellular fate of nanomedicines: Implication for rational design. Asian Journal of Pharmaceutical Sciences 8: 1-10.
    連結：
13. 13. NICDLAOS E. MADIAS MDJTH, M.D (1978) Platinum Nephrotoxicity. 65.
    連結：
14. 14. Adelstein DJ, Saxton JP, Rybicki LA, Esclamado RM, Wood BG, et al. (2006) Multiagent concurrent chemoradiotherapy for locoregionally advanced squamous cell head and neck cancer: mature results from a single institution. J Clin Oncol 24: 1064-1071.
    連結：
15. 15. Sarah D. Brown PN, Jo-Ann Smith, David Stirling.,et al (2010) Gold Nanoparticles for the Improved Anticancer Drug Delivery of the Active Component of Oxaliplatin. JACS.
    連結：
16. 16. Slowing, II, Vivero-Escoto JL, Wu CW, Lin VS (2008) Mesoporous silica nanoparticles as controlled release drug delivery and gene transfection carriers. Adv Drug Deliv Rev 60: 1278-1288.
    連結：
17. 17. Li Z, Barnes JC, Bosoy A, Stoddart JF, Zink JI (2012) Mesoporous silica nanoparticles in biomedical applications. Chem Soc Rev 41: 2590-2605.
    連結：
18. 18. Hudson SP, Padera RF, Langer R, Kohane DS (2008) The biocompatibility of mesoporous silicates. Biomaterials 29: 4045-4055.
    連結：
19. 19. Maria Kartalou et al (2001) Mechanisms of resistance to cisplatin. Mutation Research 478.
    連結：
20. 20. Mahapatro A, Singh DK (2011) Biodegradable nanoparticles are excellent vehicle for site directed in-vivo delivery of drugs and vaccines. J Nanobiotechnology 9: 55.
    連結：
21. 21. Brewer E, Coleman J, Lowman A (2011) Emerging Technologies of Polymeric Nanoparticles in Cancer Drug Delivery. Journal of Nanomaterials 2011: 1-10.
    連結：
22. 22. Cohen SM, Rockefeller N, Mukerji R, Durham D, Forrest ML, et al. (2013) Efficacy and Toxicity of Peritumoral Delivery of Nanoconjugated Cisplatin in an In Vivo Murine Model of Head and Neck Squamous Cell Carcinoma. Jama Otolaryngology-Head & Neck Surgery 139: 382-387.
    連結：
23. 23. Che E, Gao Y, Wan L, Zhang Y, Han N, et al. (2015) Paclitaxel/gelatin coated magnetic mesoporous silica nanoparticles: Preparation and antitumor efficacy in vivo. Microporous and Mesoporous Materials 204: 226-234.
    連結：
24. 24. Elzoghby AO (2013) Gelatin-based nanoparticles as drug and gene delivery systems: reviewing three decades of research. J Control Release 172: 1075-1091.
    連結：
25. 25. Egeblad M, Werb Z (2002) New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2: 161-174.
    連結：
26. 26. Doshi N, Mitragotri S (2009) Designer Biomaterials for Nanomedicine. Advanced Functional Materials 19: 3843-3854.
    連結：
27. 27. Panyam J, Labhasetwar V (2003) Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Advanced Drug Delivery Reviews 55: 329-347.
    連結：
28. 28. Savjani KT, Gajjar AK, Savjani JK (2012) Drug solubility: importance and enhancement techniques. ISRN Pharm 2012: 195727.
    連結：
29. 29. Fabio Sonvico at al (2005) Folate-Conjugated Iron Oxide Nanoparticles for Solid Tumor Targeting as Potential Specific Magnetic Hyperthermia Mediators: Synthesis, Physicochemical Characterization, and in Vitro Experiments. Bioconjugate.
    連結：
30. 30. Kawano T, Yamagata M, Takahashi H, Niidome Y, Yamada S, et al. (2006) Stabilizing of plasmid DNA in vivo by PEG-modified cationic gold nanoparticles and the gene expression assisted with electrical pulses. J Control Release 111: 382-389.
    連結：
31. 31. Soundrapandian C, Sa B, Datta S (2009) Organic-inorganic composites for bone drug delivery. AAPS PharmSciTech 10: 1158-1171.
    連結：
32. 32. C.T.Kresge MEL, er al (1992) Ordered mesoporous molecular sieves synthesized by a liguid crystal template mechanism. Nature 359.
    連結：
33. 33. Si-Han Wu C-YM (2008) Mesoporous Silica Nanoparticles for Biological Applications. CHEMISTRY (The Chinese Chemical Society, Taipei) 66.
    連結：
34. 34. Bhanudas Naik NNG (2009) A Review on Chemical Methodologies for Preparation of Mesoporous Silica and Alumina Based Materials. Recent Patents on Nanotechnology 3.
    連結：
35. 35. al JCVe (1994) Synthesis of Mesoporous Materials：Liquid－Crystal Templating versus Intercalation of Layered Silicates.pdf>. Chem Mater 6.
    連結：
36. 36. Jackie Y. Ying et al. (1999) Synthesis and Applications of Supramolecular-Templated Mesoporous Materials. 38.
    連結：
37. 37. Young S, Wong M, Tabata Y, Mikos AG (2005) Gelatin as a delivery vehicle for the controlled release of bioactive molecules. J Control Release 109: 256-274.
    連結：
38. 38. Zou Z, He D, He X, Wang K, Yang X, et al. (2013) Natural gelatin capped mesoporous silica nanoparticles for intracellular acid-triggered drug delivery. Langmuir 29: 12804-12810.
    連結：
39. 39. Franchi A, Santucci M, Masini E, Sardi I, Paglierani M, et al. (2002) Expression of matrix metalloproteinase 1, matrix metalloproteinase 2, and matrix metalloproteinase 9 in carcinoma of the head and neck. Cancer 95: 1902-1910.
    連結：
40. 40. I. Shimal YS, J. Kusukawal, R. Nakan et al, (1993) Production of matrix metalloproteinase 9 (92-kDa gelatinase) by human oesophageal squamous cell carcinoma in response to epidermal growth factor. Cancer.
    連結：
41. 41. Javed F, Al-Hezaimi K, Al-Rasheed A, Almas K, Romanos GE (2010) Implant survival rate after oral cancer therapy: a review. Oral Oncol 46: 854-859.
    連結：
42. 43. R.Hupp J (1999) Oral cancer Complications of therapy. ORAL SURGERY ORAL MEDICINE ORAL PATHOLOGY 88.
    連結：
43. 44. Wu XZ (2006) A new classification system of anticancer drugs - based on cell biological mechanisms. Med Hypotheses 66: 883-887.
    連結：
44. 45. Rabik CA, Dolan ME (2007) Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev 33: 9-23.
    連結：
45. 46. Galluzzi L, Senovilla L, Vitale I, Michels J, Martins I, et al. (2012) Molecular mechanisms of cisplatin resistance. Oncogene 31: 1869-1883.
    連結：
46. 47. al DBe (1995) Cisplatin and DNA repair in cancer chemotherapy. TIBS 2 20.
    連結：
47. 48. Alice V.Klein et al. (2009) Platinum Drug Distribution in cancer cells and tumors. Chem Rev 109.
    連結：
48. 49. Deborah B. et al (1996) Cisplatin-DNA Adducts by the Mammalian Excision Nuclease. biochemical.
    連結：
49. 50. al BGe (2007) Synthesis and Functionalization of a Mesoporous Silica Nanoparticle Based on the Sol–Gel Process and Applications in Controlled Release. Acc Chem Res 40.
    連結：
50. 51. Mindell JA (2012) Lysosomal acidification mechanisms. Annu Rev Physiol 74: 69-86.
    連結：
51. 52. Ahn B, Park J, Singha K, Park H, Kim WJ (2013) Mesoporous silica nanoparticle-based cisplatin prodrug delivery and anticancer effect under reductive cellular environment. Journal of Materials Chemistry B 1: 2829.
    連結：
52. 53. Wang T, Chai F, Fu Q, Zhang L, Liu H, et al. (2011) Uniform hollow mesoporous silica nanocages for drug delivery in vitro and in vivo for liver cancer therapy. Journal of Materials Chemistry 21: 5299.
    連結：
53. 54. al HMe (2013) Codelivery of an Optimal Drug/siRNA Combination Using Mesoporous Silica Nanoparticles To Overcome Drug Resistance in Breast Cancer in Vitro and in Vivo. ACS NANO.
    連結：
54. 55. Liu X, Yu D, Jin C, Song X, Cheng J, et al. (2014) A dual responsive targeted drug delivery system based on smart polymer coated mesoporous silica for laryngeal carcinoma treatment. New J Chem 38: 4830-4836.
    連結：
55. 56. Xu J-H, Gao F-P, Li L-L, Ma HL, Fan Y-S, et al. (2013) Gelatin–mesoporous silica nanoparticles as matrix metalloproteinases-degradable drug delivery systems in vivo. Microporous and Mesoporous Materials 182: 165-172.
    連結：
56. 57. Ruan S, He Q, Gao H (2015) Matrix metalloproteinase triggered size-shrinkable gelatin-gold fabricated nanoparticles for tumor microenvironment sensitive penetration and diagnosis of glioma. Nanoscale 7: 9487-9496.
    連結：
57. 58. al TSe (2004) Matrix metalloproteinases (MMPs) in oral diseases. Oral disease.
    連結：
58. 59. al. MRe (1984) Improved Complete Response Rate and Survival in Advanced Head and Neck Cancer After Three-Course Induction Therapy With 7 20-Hour 5-FU Infusion and Cisplatin Cancer 55.
    連結：
59. 60. Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, et al. (2008) Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 26: 3543-3551.
    連結：
60. 61. Yamano Y, Uzawa K, Saito K, Nakashima D, Kasamatsu A, et al. (2010) Identification of cisplatin-resistance related genes in head and neck squamous cell carcinoma. Int J Cancer 126: 437-449.
    連結：
61. 62. Wan X, Zhang G, Liu S (2011) pH-disintegrable polyelectrolyte multilayer-coated mesoporous silica nanoparticles exhibiting triggered co-release of cisplatin and model drug molecules. Macromol Rapid Commun 32: 1082-1089.
    連結：
62. 63. Iversen T-G, Skotland T, Sandvig K (2011) Endocytosis and intracellular transport of nanoparticles: Present knowledge and need for future studies. Nano Today 6: 176-185.
    連結：
63. 64. Tang F, Li L, Chen D (2012) Mesoporous silica nanoparticles: synthesis, biocompatibility and drug delivery. Adv Mater 24: 1504-1534.
    連結：
64. 65. Sanjiv K, Su TL, Suman S, Kakadiya R, Lai TC, et al. (2012) The novel DNA alkylating agent BO-1090 suppresses the growth of human oral cavity cancer in xenografted and orthotopic mouse models. Int J Cancer 130: 1440-1450.
    連結：
65. 66. al JASe (1995) Macropinocytosis. Trends in cell biology.
    連結：
66. 42. Pamela J. Hancock et al. (2003) Oral and Dental Management Related to Radiation Therapy for Head and Neck Cancer Canadian Dental Association 69.